First Patient Dosed in Study Assessing Immunotherapy in Metastatic Breast Cancer
The first patient was dosed in a phase 1/2 study assessing the safety and efficacy of next-generation immunotherapy to treat patients with metastatic breast cancer whose disease did not respond to at least two systemic therapies. A press release from …